X

Drug Profile

Neo 202

Alternative Names: Neo-202

Latest Information Update: 26 Dec 2023

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Neoleukin Therapeutics
Developer Neurogene Inc
Class Antineoplastics; Immunotherapies; Proteins
Mechanism of Action Interleukin 15 receptor agonists; Interleukin 2 receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes - Cancer

Highest Development Phases

Suspended Cancer

Most Recent Events

19 Dec 2023 Neurogene Inc has merged with Neoleukin Therapeutics to form Neurogene Inc
30 Mar 2023 Suspended for Cancer in USA (IV)
06 Sep 2022 Neo 202 is available for licensing as of 06 Sep 2022. https://www.neoleukin.com/science/#partners

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com